REDWOOD CITY, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Rupert D’Souza, Ph.D., M.B.A., has joined...

REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the...

-- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD --REDWOOD CITY, Calif., Oct. 09, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular...

-- Results featured in a presentation today at the Retina Society’s 54 th Annual Scientific Meeting -- -- Robust aflibercept protein expression sustained through 2 years -- -- Over 80% reduction in annualized anti-VEGF injection frequency at 2 x 10^11 vg/eye -- --...

REDWOOD CITY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of new clinical data on ADVM-022...

REDWOOD CITY, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Jim Wang, Ph.D., has been appointed senior vice...

REDWOOD CITY, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the second quarter ended June...

-- Based on latest analyses, company is revising ADVM-022 development plan to focus on  wet AMD and low doses (2 x 10^11 vg/eye and lower);  no longer planning development for DME -- -- Company to host conference call and webcast today at 1:30 pm PT / 4:30 pm ET --...

REDWOOD CITY, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Jon Williams, Ph.D., as vice...

-- Christopher J. DeRespino appointed acting CFO -- -- Peter Soparkar appointed COO -- -- Leone Patterson departs as president and CFO after five years of service -- REDWOOD CITY, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM),...